Spotlight on topiramate in epilepsy.

Abstract

Topiramate (Topamax) is a structurally novel broad-spectrum antiepileptic drug (AED) with established efficacy as monotherapy or adjunctive therapy in the treatment of adult and paediatric patients with generalized tonic-clonic seizures, partial seizures with or without generalized seizures, and seizures associated with Lennox-Gastaut syndrome. The incidence and severity of many adverse events, including CNS-related events, may be reduced through the use of slow titration to effective and well tolerated dosages. It is associated with few clinically significant interactions with other drugs, is effective when used with other AEDs, is not associated with drug-induced weight gain and, at lower dosages, does not interfere with the effectiveness of oral contraceptives. Therefore, topiramate is a valuable option as monotherapy or adjunctive therapy in the treatment of epilepsy in adult and paediatric patients.

• Authors: Katherine A Lyseng-Williamson, Lily P H Yang
• Journal: CNS drugs (CNS Drugs) Vol. 22 Issue 2 Pg. 171-4 ( 2008) ISSN: 1172-7047 [Print] New Zealand
• PMID: 18193927 (Publication Type: Journal Article, Review)

Chemical References

• Anticonvulsants
• Topiramate
• Fructose

Topics

• Anticonvulsants (therapeutic use)
• Drug Evaluation
• Epilepsy (drug therapy)
• Fructose (analogs & derivatives, therapeutic use)
• Humans
• Topiramate